Teva Pharmaceutical Industries announced on 18 October 2010 that it had received FDA approval for its Abbreviated New Drug Application for its generic version of Takeda's Prevacid (lansoprazole) SoluTab.
FDA grants approval for generic lansoprazole
Generics/News
|
Posted 03/12/2010
0
Post your comment
The Israeli generics’ giant has been granted permission to market the drug in the US, and shipment of the medication has already commenced.
Lansoprazole, which is a proton pump inhibitor, is used to treat and prevent stomach and intestinal ulcers by lowering the amount of stomach acid produced by the body.
Annual sales of Prevacid were estimated to be US$453 million in the US, according to IMS sales data.
Source: Teva Press Release. Teva Announces Launch of Generic Prevacid® SoluTab in the United States. 18 October 2010.
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment